Circadian rhythm of white blood cells during clozapine treatment

被引:28
作者
Ahokas, A
Elonen, E
机构
[1] Helsinki City Hosp, Dept Psychiat, FIN-00260 Helsinki, Finland
[2] Univ Helsinki, Dept Haematol, FIN-00290 Helsinki, Finland
关键词
diurnal variation; neutropenia; clozapine; schizophrenia;
D O I
10.1007/s002130051008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: The atypical antipsychotic clozapine is effective in the treatment of patients with refractory schizophrenia. It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine. Objective: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC). Methods: Due to the lack of efficacy of subsequent treatment of conventional and other atypical neuroleptics, treatment with clozapine was restarted after discontinuation. When the morning count of WBC began to fall, WBC count was repeated in the afternoons. Results: Careful blood cell monitoring showed a pronounced diurnal variation of WBC (2.9-4.2 x 10(9)/l in the morning and 3.6-7.1 x 10(9)/l in the afternoon) and granulocytes (0.8-1.4 x 10(9)/l and 2.9-5.5 x 10(9)/l, respectively). Conclusions: Some patients may thus have a spuriously low cell count and may be unnecessarily denied effective treatment.
引用
收藏
页码:301 / 302
页数:2
相关论文
共 12 条
[1]   CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES [J].
ALVIR, JMJ ;
LIEBERMAN, JA ;
SAFFERMAN, AZ ;
SCHWIMMER, JL ;
SCHAAF, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :162-167
[2]   AGRANULOCYTOSIS IN PATIENTS TREATED WITH CLOZAPINE - STUDY OF FINNISH EPIDEMIC [J].
AMSLER, HA ;
TEERENHOVI, L ;
BARTH, E ;
HARJULA, K ;
VUOPIO, P .
ACTA PSYCHIATRICA SCANDINAVICA, 1977, 56 (04) :241-248
[3]   Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland [J].
Atkin, K ;
Kendall, F ;
Gould, D ;
Freeman, H ;
Lieberman, J ;
OSullivan, D .
BRITISH JOURNAL OF PSYCHIATRY, 1996, 169 (04) :483-488
[4]  
BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746
[5]  
Gerson S L, 1992, Drug Saf, V7 Suppl 1, P17
[6]  
Kapur S, 1999, AM J PSYCHIAT, V156, P286
[7]  
Lieberman JA, 1998, J CLIN PSYCHIAT, V59, P38
[8]  
Marder SR, 1996, J CLIN PSYCHIAT, V57, P26
[9]  
MELTZER HY, 1995, AM J PSYCHIAT, V152, P183
[10]  
PEACOCK L, 1994, J CLIN PSYCHIAT, V55, P44